In This Section

Program

Wednesday, June 24

Thursday, June 25

Friday, June 26

Saturday, June 27

Wednesday, June 24

REGISTRATION

1-7 p.m.

WELCOME AND OPENING Keynote

  • 5:10 p.m. | Opening Keynote Lecture
    Ron Levy, Stanford University, Stanford, California

Plenary Session 1: Antibodies through the eras

6-7:50 p.m.

  • 6 p.m. | Dave Maloney Fred Hutch Seattle, Washington
  • 6:30 p.m. | Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, New York
  • 7 p.m. | Elicia Penuel, Genentech/Roche, San Francisco, California
  • 7:30 p.m. | Panel Discussion / Q&A

Reception

7:30-9:30 p.m.

Thursday, June 25

Workshop: AI in lymphoma: foundation models and beyond

7:15-7:45 a.m.

  • Jansen Seheult, Mayo Clinic, Rochester, Minnesota, Minneapolis 

Plenary Session 2: Next Generation Clinical Assessment

8-9:50 a.m.

  • 8 a.m. | Davide Rossi, Oncology Institute of Southern Switzerland, Bellinzona, Ticino, Switzerland
  • 8:30 a.m. | Genetics to inform therapy in lymphoma
    Margaret Shipp, Dana Farber Cancer Institute, Boston, Massachusetts
  • 9 a.m. | Integrating the microenvironment and omics into clinical workflows
    Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 9:30 a.m. | Panel Discussion / Q&A

Break

9:50-10:10 a.m.

Plenary Session 3: The Lymphoma Microenvironment

10:10-12 p.m.

  • 10:10 a.m. | Sandrine Roulland, Centre d’Immunologie de Marseille-Luminy, Marseille, France
  • 10:40 a.m. | Using the microenvironment to predict response to therapy
    Justin Kline, University of Chicago, Chicago, Illinois
  • 11:10 a.m. | Hodgkin lymphoma tumor microenvironment
    Christian Steidl, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
  • 11:40 | Panel Discussion / Q&A

Lunch

12-2 p.m.

Plenary Session 4: Spatial Analysis of Lymphoma

2-3:50 p.m.

  • 2 p.m. | David Scott, University of British Columbia, Vancouver, British Columbia, Canada
  • 2:30 p.m. | Transformation
    Erin Parry, Dana Farber Cancer Institute, Boston, Massachusetts
  • 3:30 p.m. | Panel Discussion / Q&A

Break

3:50-4:10 p.m.

Spotlight on Proffered Abstracts

4:10-5:10 p.m.

Poster Session

5:30-7:30 p.m.

Friday, June 26

Workshop: ctDNA analyses of lymphoid malignancies

7:15-7:45 a.m.

  • Mark Roshchewski, Memorial Sloan Kettering Cancer, New York, New York

Plenary Session 5: New Targeted Therapeutic Strategies in Lymphoma

8-9:50 a.m.

  • 8 a.m. | Kerry Rogers, Ohio State University, Columbus, Ohio 
  • 8:30 a.m. | Chemotherapy-free strategies for large B-cell lymphoma
    Mark Roschewski, Memorial Sloan Kettering Cancer Center, New York, New York
  • 9 a.m. | Integrating novel agents into rational combinations
    Jason Westin, MD Anderson Cancer Center, Houston, Texas 
  • 9:30 a.m. | Panel Discussion / Q&A

break

9:50-10:10 a.m.

Plenary Session 6: Degraders in Lymphoma

10:10 a.m. -12 p.m.

  • 10:10 a.m. | Exploiting the E3 ligase FBXO21 as a novel therapeutic target and degrader in lymphoma
    Shannon Buckley, University of Utah, Salt Lake City, Utah
  • 10:40 a.m. | Resistance to BTK degraders
    Francesco Bertoni, Oncology Institute of Southern Switzerland, Bellinzona, Ticino, Switzerland
  • 11:10 a.m. | Justin Taylor, University of Miami Miller School of Medicine, Miami, Florida
  • 11:40 p.m. | Panel Discussion / Q&A

break

12-2 p.m.

Plenary Session 7: Rare Lymphomas

2-4:20 p.m.

  • 2 p.m. | Jean Koff, Winship Cancer Institute of Emory University, Atlanta, Georgia
  • 2:30 p.m. | Navigating the landscape of peripheral T-cell lymphomas
    Teresa Palomero, Columbia University, New York, New York
  • 3 p.m. | Updates on the treatment of Primary CNS Lymphoma
    Christian Grommes, Memorial Sloan Kettering Cancer Center, New York, New York, USA 
  • 3:30 p.m. | Panel Discussion / Q&A

BREAK

3:50-4:10 p.m.

Plenary Session 8: Advances in Cell Therapy

4:10-6 p.m.

  • 4:10 p.m. | Novel CAR-T cells in lymphoma
    Marcela Maus, Massachusetts General Hospital, Boston, Massachusetts
  • 4:40 p.m. | Armored CAR T cells
    Sarwish Rafiq, Winship Cancer Institute of Emory University, Atlanta, Georgia
  • 5:10 p.m. | Novel engineering strategies for CAR T cell therapy in lymphoma
    Laura Evgin, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
  • 5:40 p.m. | Panel Discussion / Q&A

break

6-6:20 p.m.

Hematologic Malignancies Working Group Session 

6:20-8:20 p.m.

Details to be announced

Saturday, June 27

Workshop: Leveraging technologies for the lymphoma microenvironment

7:15-7:45 a.m.

  • Xubin Li, The University of Texas MD Anderson Cancer Center, Houston, Texas

Closing Keynote Lecture

8-9 a.m.

  • Michel Nussenzweig, Rockefeller University, New York, New York

Plenary Session 9: Germinal Center Biology and Lymphomas

9-11 a.m.

  • 9:20 a.m. | Cells of origin for lymphoma
    Dinis Pedro Parente Calado, Francis Crick Institute, London, England, United Kingdom
  • 9:50 a.m. | Ari Melnick, Josep Carreras Institute, Badalona, Catalonia, Spain
  • 10:30 a.m. | Panel Discussion / Q&A

break

10:50-11:10 a.m.

Plenary Session 10: Epigenetics

11:10-1:15 p.m.

  • 11:10 a.m. | Targeting the BCL6 transcription factor in lymphoma
    Michael Green, The University of Texas MD Anderson Cancer Center,  Houston, Texas  
  • 11:40 a.m. | Wendy Beguelin, New York University, New York, New York
  • 12:10 p.m. | Laura Pasqualucci, Columbia University, New York, New York
  • 12:40 p.m. | Panel Discussion / Q&A

Closing Remarks

1 p.m.